Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARA | Q07869 | 7/20 | 0.73 |
| ▸ | PPARG | P37231 | 3/20 | 0.73 |
| ▸ | FABP2 | P12104 | 1/20 | 0.73 |
| ▸ | SLC22A12 | Q96S37 | 1/20 | 0.73 |
| ▸ | ELANE | P08246 | 4/20 | 0.65 |
| ▸ | HPGD | P15428 | 2/20 | 0.65 |
| ▸ | CYP1A2 | P05177 | 3/20 | 0.63 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.63 |
| ▸ | MAPT | P10636 | 3/20 | 0.63 |
| ▸ | MEN1 | O00255 | 2/20 | 0.63 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.63 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.63 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.63 |
| ▸ | ABCB11 | O95342 | 2/20 | 0.63 |
| ▸ | TSHR | P16473 | 2/20 | 0.63 |
| ▸ | HTR2A | P28223 | 2/20 | 0.63 |
| ▸ | PMP22 | Q01453 | 2/20 | 0.63 |
| ▸ | LMNA | P02545 | 2/20 | 0.63 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.63 |
| ▸ | USP2 | O75604 | 1/20 | 0.63 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20076975 | 0.90 | ELANE (0.60) | PPARAPPARGFABP2SLC22A12ELANE | |
| SCHEMBL30657556 | 0.86 | PPARA (0.69) | PPARAPPARGFABP2SLC22A12ELANE | |
| SCHEMBL10552166 | 0.85 | ELANE (0.55) | PPARAPPARGFABP2SLC22A12ELANE | |
| SCHEMBL13984052 | 0.84 | PPARA (0.77) | PPARAPPARGFABP2SLC22A12ELANE | |
| SCHEMBL822492 | 0.84 | PPARA (0.77) | PPARAPPARGFABP2SLC22A12ELANE | |
| Fenofibric Acid SCHEMBL16377 | 0.84 | PPARA (1.00) | PPARAPPARGFABP2SLC22A12ELANE | |
| SCHEMBL196705 | 0.84 | PPARA (0.57) | PPARAPPARGFABP2SLC22A12ELANE | |
| SCHEMBL3418004 | 0.83 | ELANE (0.66) | PPARAPPARGFABP2SLC22A12ELANE | |
| SCHEMBL17302417 | 0.83 | LMNA (0.61) | PPARAPPARGFABP2SLC22A12ELANE | |
| SCHEMBL5281549 | 0.83 | ELANE (0.64) | PPARAPPARGFABP2SLC22A12ELANE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2019028096-A1 | METHODS AND COMPOSITIONS FOR TREATING CANCER | THE WISTAR INSTITUTE OF ANATOMY AND BIOLOGY (US) | 2019-02-07 | — | — | WO | disclosed |
| US-20170144972-A1 | METHODS OF LOWERING PROPROTEIN CONVERTASE SUBTILISIN/KEXIN TYPE 9 (PCSK9) | CATABASIS PHARMACEUTICALS, INC. | 2017-05-25 | — | — | US | disclosed |
| US-20150344430-A1 | METHODS OF LOWERING PROPROTEIN CONVERTASE SUBTILISIN/KEXIN TYPE 9 (PCSK9) | CATABASIS PHARMACEUTICALS, INC. | 2015-12-03 | — | — | US | disclosed |
| US-20120040897-A1 | NOVEL DERIVATIVES OF ACYL CYANOPYRROLIDINES | SUN PHARMA ADVANCED RESEARCH COMPANY LTD. (IN) | 2012-02-16 | — | — | US | disclosed |
| US-20120040897-A1 | NOVEL DERIVATIVES OF ACYL CYANOPYRROLIDINES | SUN PHARMA ADVANCED RESEARCH COMPANY LTD. (IN) | 2012-02-16 | — | — | US | disclosed |
| US-20100081715-A1 | Formulation Comprising Fenofibric Acid, A Physiologically Acceptable Salt or Derivative Thereof | ROSENBERG JOERG | 2010-04-01 | — | — | US | disclosed |
| US-20090263477-A1 | SALTS OF FENOFIBRIC ACID AND PHARMACEUTICAL FORMULATIONS THEREOF | ABBOTT LABORATORIES (US) | 2009-10-22 | — | — | US | disclosed |
| US-20080051411-A1 | choline fenofibrate, or fenofibric acid salts of ethanolamine, diethanolamine, piperazine, calcium or tromethamine; salts have improved photostability; hyperlipidemia or coronary heart diseases | ABBVIE INC. | 2008-02-28 | — | — | US | disclosed |
| US-7259186-B2 | Salts of fenofibric acid and pharmaceutical formulations thereof | ABBOTT LABORATORIES (US) | 2007-08-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090263477-A1 | SALTS OF FENOFIBRIC ACID AND PHARMACEUTICAL FORMULATIONS THEREOF | FABP2, FABP1, FABP3 | PPARA 8/4885PPARG 11/4885FABP2 1/4885 |
| US-20120040897-A1 | NOVEL DERIVATIVES OF ACYL CYANOPYRROLIDINES | NR1D2, STARD10, NR1D1 | PPARA 1459/4885PPARG 1825/4885FABP2 3538/4885 |
| US-20150344430-A1 | METHODS OF LOWERING PROPROTEIN CONVERTASE SUBTILISIN/KEXIN TYPE 9 (PCSK9) | PCSK9, PCSK6, PCSK7 | PPARA 196/4885PPARG 285/4885FABP2 36/4885 |
| US-20170144972-A1 | METHODS OF LOWERING PROPROTEIN CONVERTASE SUBTILISIN/KEXIN TYPE 9 (PCSK9) | PCSK9, PCSK6, PCSK7 | PPARA 196/4885PPARG 285/4885FABP2 36/4885 |
| US-20100081715-A1 | Formulation Comprising Fenofibric Acid, A Physiologically Acceptable Salt or Derivative Thereof | FABP2, CEL, SLC10A2 | PPARA 17/4885PPARG 51/4885FABP2 1/4885 |
| US-20080051411-A1 | choline fenofibrate, or fenofibric acid salts of ethanolamine, diethanolamine, piperazine, calcium or tromethamine; salts have improved photostability; hyperlipidemia or coronary heart diseases | FABP2, FABP3, FABP1 | PPARA 20/4885PPARG 118/4885FABP2 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.